Conditions:  Malignant Solid Neoplasm;  Recurrent Adrenal Gland Pheochromocytoma;  Recurrent Ectomesenchymoma;  Recurrent Ependymoma;  Recurrent Ewing Sarcoma;  Recurrent Hepatoblastoma;  Recurrent Kidney Wilms Tumor;  Recurrent Langerhans Cell Histiocytosis;  Recurrent Malignant Germ Cell Tumor;  Recurrent Malignant Glioma;  Recurrent Medulloblastoma;  Recurrent Melanoma;  Recurrent Neuroblastoma;  Recurrent Non-Hodgkin Lymphoma;  Recurrent Osteosarcoma;  Recurrent Peripheral Primitive Neuroectodermal Tumor;  Recurrent Rhabdoid Tumor;  Recurrent Rhabdoid Tumor of the Kidney;  Recurrent Rhabdomyosarcoma;  Recurrent Soft Tissue Sarcoma;  Recurrent Thyroid Gland Carcinoma;  Recurrent WHO Grade 2 Glioma;  Refractory Adrenal Gland Pheochromocytoma;  Refractory Ependymoma;  Refractory Ewing Sarcoma;  Refractory Hepatoblastoma;  Refractory Langerhans Cell Histiocytosis;  Refractory Malignant Germ Cell Tumor;  Refractory Malignant Glioma;  Refractory Medulloblastoma;  Refractory Melanoma;  Refractory Neuroblastoma;  Refractory Non-Hodgkin Lymphoma;  Refractory Osteosarcoma;  Refractory Peripheral Primitive Neuroectodermal Tumor;  Refractory Rhabdoid Tumor;  Refractory Rhabdoid Tumor of the Kidney;  Refractory Rhabdomyosarcoma;  Refractory Soft Tissue Sarcoma;  Refractory Thyroid Gland Carcinoma;  Refractory WHO Grade 2 Glioma
Intervention: Â Drug:Â Tipifarnib
Sponsor:  National Cancer Institute (NCI)
**RECRUITING NOW**
Intervention: Â Drug:Â Tipifarnib
Sponsor:  National Cancer Institute (NCI)
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
